October 20, 2017 07:17 AM EDTUpdated 10:35 AM
People
Financing
Peer Review

Peer Re­view: Eye­ing a $350M ven­ture fund, Nex­tech re­cruits Third Rock’s Jakob Loven for the team

John Carroll

Editor & Founder

Nex­tech In­vest closed its fourth on­col­o­gy ven­ture fund in 2014 with $64 mil­lion, putting it in­to play at a transat­lantic group of can­cer drug de­vel­op­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times